^
Association details:
Biomarker:BRAF V600E
Cancer:Ganglioglioma
Drug:Mekinist (trametinib) (MEK inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Adjuvant Treatment...Useful in Certain Circumstance...Pilocytic astrocytoma, PXA, ganglioglioma if BRAF V600E activating mutation…trametinib
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Melanoma)
New
Excerpt:
MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naive patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA approved test.